Sahil Khanna, MBBS, MS, FACG

Mayo Clinic
Rochester, MN

Presentation(s):

• 56 - An Interim Analysis of a Phase 3, Open-Label Study Indicates Efficacy and Safety of RBX2660 in Patients With Recurrent Clostridioides difficile Infection

  Wednesday, October 26, 2022
  8:40 AM – 8:50 AM ET

• 63 - An Open-Label Study (ECOSPOR IV) to Evaluate the Safety, Efficacy and Durability of SER-109, an Investigational Oral Microbiome Therapeutic, in Adults With Recurrent Clostridioides difficile Infection (rCDI)

  Wednesday, October 26, 2022
  9:50 AM – 10:00 AM ET